Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
- Changes in use of long-acting reversible contraceptive methods among U.S. women, 2009–2012.Obstet Gynecol. 2015; 126: 917-927
- The relationship between long-acting reversible contraception and insurance coverage: a retrospective analysis.Contraception. 2016; 93: 266-272
- Declines in unintended pregnancy in the United States, 2008–2011.N Engl J Med. 2016; 374: 843-852
- Obstet Gynecol. 2007; 110: 1493-1495
- ACOG Practice Bulletin No. 121: long-acting reversible contraception: Implants and intrauterine devices.Obstet Gynecol. 2011; 118: 184-196
- Meeting the contraceptive needs of teens and young adults: youth-friendly and long-acting reversible contraceptive services in U.S. family planning facilities.J Adolesc Health. 2013; 52: 284-292
- Effectiveness of long-acting reversible contraception.N Engl J Med. 2012; 366: 1998-2007
- Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project.Contraception. 2011; 84: 493-498
- Do knowledge and attitudes regarding intrauterine devices predict interest in their use?.Womens Health Issues. 2015; 25: 359-365
- Evidence-based IUD practice: family physicians and obstetrician-gynecologists.Fam Med. 2012; 44: 637-645
- Did increasing use of highly effective contraception contribute to declining abortions in Iowa?.Contraception. 2015; 91: 167-173
- A comparison of contraceptive procurement pre- and post-benefit change.Contraception. 2007; 76: 360-365
- Game change in Colorado: widespread use of long-acting reversible contraceptives and rapid decline in births among young, low-income women.Perspect Sex Reprod Health. 2014; 46: 125-132
- The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception.Am J Obstet Gynecol. 2010; 203: 115.e1-115.e7
- Accessibility of long-acting, reversible contraception (LARC) in Federally Qualified Health Centers (FQHCs).Contraception. 2014; 89: 91-96
- Contraceptive Needs and Services, 2014 Update.Guttmacher Institute, New York2016
- Liletta IUD may offer cost savings to 340B covered entities.(September 12, 2016. Accessed January 16, 2018 from:)
- Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system.Contraception. 2015; 92: 10-16
- 340 B Drug Pricing Program.(from:)https://www.hhs.gov/opa/grants-and-funding/340b-drug-pricing-program/index.htmlDate accessed: September 8, 2017
- HER Salt Lake.(from:)http://www.hersaltlake.orgDate accessed: September 8, 2017
- Interrupted time series regression for the evaluation of public health interventions: a tutorial.Int J Epidemiol. 2017; : 348-355
- Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations.J Clin Epidemiol. 2015; 68: 950-956
- A reanalysis of cluster randomized trials showed interrupted time-series were valuable in health system evaluation.J Clin Epidemiol. 2015; 68: 324-333https://doi.org/10.1016/j.jclinepi.2014.10.003
- On time series analysis of public health and biomedical data.in: Johns Hopkins University, Dept. of Biostatistics Working Papers. Working Paper 54. 2004 (from:)http://biostats.bepress.com/jhubiostat/paper54Date accessed: September 15, 2017
- Testing the autocorrelation structure of disturbances in ordinary least squares and instrumental variables regression.in: Technical Working Paper No. 92. National Bureau of Economic Research, Cambridge, MA1990
☆Initial findings were presented at the Society of Family Planning's annual North American Forum on Family Planning held in Denver, CO, November 2016.
☆☆The findings and conclusions in this article are those of the authors and do not necessarily represent the views of Planned Parenthood Federation of America, Inc.
★Conflict of interest: The Department of Obstetrics and Gynecology, University of Utah, receives contraceptive clinical trials research funding from Bayer, Bioceptive, Contramed, Medicines 360, Merck and Teva.
★★Funding: This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.
☆☆☆J.N.S. and D.K.T. receive support from the Eunice Kennedy Shriver National Institute of Child Health & Human Development and the Office of Research on Women's Health of the National Institute of Health under Awarded Number K12HD085852 and D.K.T. under K24HD087436.